The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies

The document from April 1, 2019, reviewed the potential of Stromal Vascular Fraction (SVF) in treating male sexual dysfunction, particularly erectile dysfunction (ED) and Peyronie's disease (PD). It covered 5 preclinical studies on ED, 1 Phase 1 clinical trial on ED involving 17 men, and 1 clinical study on PD with 11 men. Preclinical studies indicated improvements in erectile function in animal models, but there were issues with long-term retention of SVF components. The clinical ED study showed some improvement in erectile function post-prostatectomy, and the PD study reported subjective improvements when SVF was combined with shock wave therapy. Despite these findings, the review concluded that there is insufficient data on the efficacy and safety of SVF, highlighting the need for more research, including well-designed clinical trials and basic science investigations, to standardize SVF treatment and ensure its safety before it can be recommended for widespread clinical use.